Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 28, 2015, Pages 8756-8761

  Kim, Chun Hyung ^a,b   Han, Baek Soo ^a,c   Moon, Jisook ^a,d   Kim, Deog Joong ^a   Shin, Joon ^e   Rajan, Sreekanth ^e   Nguyen, Quoc Toan ^e   Sohn, Mijin ^c   Kim, Won Gon ^c   Han, Minjoon ^a   Jeong, Inhye ^a   Kim, Kyoung Shim ^c   Lee, Eun Hye ^f   Tu, Yupeng ^g   Naffin Olivos, Jacqueline L ^g   Park, Chang Hwan ^f   Ringe, Dagmar ^g   Yoon, Ho Sup ^e,h   Petsko, Gregory A ^g,i   Kim, Kwang Soo ^a  

^a MCLEAN HOSPITAL   (United States)

^b Seoul National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d CHA University   (South Korea)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f Hanyang University   (South Korea)

^g BRANDEIS UNIVERSITY   (United States)

^h Kyung Hee University   (South Korea)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Agonist; Drug target; NR4A2; Nurr1; Parkinson's disease

Indexed keywords

AMODIAQUINE; CHLOROQUINE; NEUROPROTECTIVE AGENT; NUCLEAR RECEPTOR RELATED FACTOR 1; NUCLEAR RECEPTOR RELATED FACTOR 1 AGONIST; OXIDOPAMINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG TARGETING; DYSKINESIA; GENE EXPRESSION; GENE REPRESSION; LIGAND BINDING; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RAT MODEL; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PSYCHOLOGY;

ANIMALIA; RATTUS;

AMODIAQUINE; ANIMALS; BEHAVIOR, ANIMAL; CHLOROQUINE; DISEASE MODELS, ANIMAL; LIGANDS; NEUROGENESIS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; OXIDOPAMINE; PARKINSON DISEASE; RATS;

EID: 84937232326     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509742112     Document Type: Article

References (26)

1. Dauer W, Przedborski S (2003) Parkinson's disease: Mechanisms and models. Neuron 39(6):889-909.
2. Meissner WG, et al. (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10(5):377-393.
3. Obeso JA, et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16(6):653-661.
4. Smidt MP, Burbach JP (2007) How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8(1):21-32.
5. Ang SL (2006) Transcriptional control of midbrain dopaminergic neuron development. Development 133(18):3499-3506.
6. Abeliovich A, Hammond R (2007) Midbrain dopamine neuron differentiation: Factors and fates. Dev Biol 304(2):447-454.
7. Chung S, et al. (2009) Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 5(6):646-658.
8. Castillo SO, et al. (1998) Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci 11(1-2):36-46.
9. Saucedo-Cardenas O, et al. (1998) Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 95(7):4013-4018.
10. Zetterström RH, et al. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276(5310):248-250.
11. Kadkhodaei B, et al. (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 29(50):15923-15932.
12. Saijo K, et al. (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137(1):47-59.
13. Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH (2002) Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 450(3):203-214.
14. Chu Y, et al. (2006) Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494(3):495-514.
15. Le WD, et al. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33(1):85-89.
16. Hering R, et al. (2004) Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 62(7):1231-1232.
17. Nichols WC, et al. (2004) Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord 19(6):649-655.
18. Jiang C, et al. (2005) Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 191(1):154-162.
19. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918-934.
20. Kim KS, et al. (2003) Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem 85(3):622-634.
21. Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14(2):121-141.
22. McMorrow JP, Murphy EP (2011) Inflammation: A role for NR4A orphan nuclear receptors? Biochem Soc Trans 39(2):688-693.
23. Wang Z, et al. (2003) Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423(6939):555-560.
24. Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. Behav Brain Res 179(1):76-89.
25. D'Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: Toxic metabolite MPP+ binds to neuromelanin. Science 231(4741):987-989.
26. D'Amato RJ, et al. (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327(6120):324-326.